Skip to main content

Advertisement

Log in

Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective

To assess the association between serum triglyceride levels and cancer risk.

Methods

The metabolic syndrome and cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden; the current study included data on 257,585 men and 256,512 women. The mean age at study entry was 43.8 years for men and 44.2 years for women. The mean follow-up time was 13.4 years (SD = 8.5) for men and 11.9 years (SD = 7.2) for women. Excluding the first year of follow-up, 23,060 men and 15,686 women were diagnosed with cancer. Cox regression models were used to calculate relative risk (RR) of cancer for triglyceride levels in quintiles and as a continuous variable. RRs were corrected for random error by use of regression dilution ratio.

Results

Relative risk for top quintile versus bottom quintile of triglycerides of overall cancer was 1.16 (95% confidence interval 1.06–1.26) in men and 1.15 (1.05–1.27) in women. For specific cancers, significant increases for top quintile versus bottom quintile of triglycerides among men were found for cancers of the colon, respiratory tract, the kidney, melanoma and thyroid and among women, for respiratory, cervical, and non-melanoma skin cancers.

Conclusion

Data from our study provided evidence for a possible role of serum triglycerides in cancer development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Sarwar N, Danesh J, Eiriksdottir G et al (2007) Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 115(4):450–458

    Article  CAS  PubMed  Google Scholar 

  2. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298(3):309–316

    Article  CAS  PubMed  Google Scholar 

  3. Ridker PM (2008) Fasting versus non-fasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 54(1):11–13

    Article  CAS  PubMed  Google Scholar 

  4. Iso H, Naito Y, Sato S et al (2001) Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153(5):490–499

    Article  CAS  PubMed  Google Scholar 

  5. Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR (1986) Is the level of serum triglyceride a significant predictor of coronary death in “normocholesterolemic” subjects? The Paris Prospective Study. Am J Epidemiol 124(4):624–632

    CAS  PubMed  Google Scholar 

  6. Fontbonne A, Eschwège E, Cambien F et al (1989) Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32(5):300–304

    Article  CAS  PubMed  Google Scholar 

  7. Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86(3):836–842

    Google Scholar 

  8. Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131:3109–3120

    Google Scholar 

  9. Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169:1505–1522

    Article  CAS  PubMed  Google Scholar 

  10. Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L (1997) Risk factors for malignant diseases: a cohort study on a population of 22, 946 Icelanders. Cancer Epidemiol Biomarkers Prev 6(11):863–873

    CAS  PubMed  Google Scholar 

  11. Ulmer H, Borena W, Rapp K et al (2009) Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 101(7):120–126

    Article  Google Scholar 

  12. McKeown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3(8):687–695

    CAS  PubMed  Google Scholar 

  13. Tsushima M, Nomura AM, Lee J, Stemmermann GN (2005) Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci 50(3):499–505

    Article  PubMed  Google Scholar 

  14. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L (2001) Breast cancer risk in ex-smokers in relation to body mass index, weight gain and blood lipid levels. Eur J Cancer Prev 10(3):281–287

    Article  CAS  PubMed  Google Scholar 

  15. Gaard M, Tretli S, Urdal P (1994) Risk of breast cancer in relation to blood lipids: a prospective study of 31, 209 Norwegian women. Cancer Causes Control 5(6):501–509

    Article  CAS  PubMed  Google Scholar 

  16. Lund HL, Wisloff TF, Holme I, Nafstad P (2006) Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164:769–774

    Article  Google Scholar 

  17. Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164:1094–1102

    Article  PubMed  Google Scholar 

  18. Emberson JR, Whincup PH, Morris RW, Walker M, Lowe GD, Rumley A (2004) Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil 11(2):125–134

    Article  PubMed  Google Scholar 

  19. Stocks T, Borena W, Strohmaier S et al (2009) Cohort profile: the metabolic syndrome and cancer project (Me-Can). Int J Epidemiol 39(3):660–667

    Article  PubMed  Google Scholar 

  20. Borena W, Stocks T, Strohmaier S et al (2009) Long-term temporal trends in cardiovascular and metabolic risk factors. Wien Klin Wochenschr 121(19–20):623–630

    Article  PubMed  Google Scholar 

  21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25):3143–3421

    Google Scholar 

  22. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R (1999) Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 150:341–353

    CAS  PubMed  Google Scholar 

  23. Wood AM, White I, Thompson SG, Lewington S, Danesh J (2006) Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27, 247 adults in 15 prospective studies. Int J Epidemiol 35:1570–1578

    Article  PubMed  Google Scholar 

  24. Inoue M, Noda M, Kurahashi N et al (2009) Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 18(3):240–247

    Article  PubMed  Google Scholar 

  25. Al-Azzawi F, Wahib M (2002) Estrogen and colon cancer: current issues. Climacteric 5(1):3–14

    CAS  PubMed  Google Scholar 

  26. Crandall CJ (1999) Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 9:1155–1166

    Google Scholar 

  27. Brunzell JD (2007) Clinical practice. Hypertriglyceridemia. N Engl J Med 357(10):1009–1017

    Article  CAS  PubMed  Google Scholar 

  28. Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51(3):794–798

    CAS  PubMed  Google Scholar 

  29. Kamata H, Hirata H (1999) Redox regulation of cellular signalling. Cell Signal 11(1):1–14

    Article  CAS  PubMed  Google Scholar 

  30. Warnick GR, Nakajima K (2008) Fasting versus nonfasting triglycerides: implications for laboratory measurements. Clin Chem 54(1):14–16

    Article  CAS  PubMed  Google Scholar 

  31. Yuan G, Al-Shali KZ, Hegele RA (2007) Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176(8):1113–1120

    PubMed  Google Scholar 

Download references

Acknowledgments

Funding sources of this study are World Cancer Research Fund International (WCRF International) 2007/2009 and the Austrian National Bank Grant OENB-12737 (to H.U.).

Conflict of interest

None declared

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hanno Ulmer.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 22 kb)

Supplementary material 2 (DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borena, W., Stocks, T., Jonsson, H. et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 22, 291–299 (2011). https://doi.org/10.1007/s10552-010-9697-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-010-9697-0

Keywords

Navigation